A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of SPI Implant

Dental Implant Bone Loss Clinical Trial

— SPI  

Official title:

An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02367261
• Other study ID #: SPI-001
• Status: Completed
• Phase: Phase 4
• First received: February 12, 2015
• Last updated: June 27, 2017
• Start date: November 2014
• Est. completion date: June 2017

Study information

• Verified date: June 2017
• Source: Alpha - Bio Tec Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current prospective clinical study's aim is to determine ABT's SPI implant survival rate, crestal interproximal bone resorption during 24 months post implant insertion and to assimilate the drilling sequence during the clinical use of SPI implants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 88
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Men and women over the age of 18 years who need implantation of 1-4 implants.

2. Patients who are able to understand the requirements of the study, and are willing and able to comply with its instructions and schedules.

3. Patients who had provided written informed consent to participate in the study prior to any study procedure.

4. Patients in general good health in the opinion of the principal investigator as determined by medical history and oral examination.

Exclusion Criteria:

1. Immediate loaded implants.

2. Patient requiring bone augmentation

3. Treatment with anticoagulant drugs (INR under 1.8) or bisphosphonates.

4. Treatment with anticonvulsants drugs.

5. Untreated Periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements.

6. Patients with history of alcohol, narcotics or drug abuse.

7. Patients under steroid therapy.

8. Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment or who have been administered radiotherapy in the last 5 years.

Patients through at anytime received radiotherapy to the head and neck region will be excluded anyway.

9. Metabolic bone disorders and/or bone augmentation.

10. Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia.

11. Degenerative diseases.

12. Osteoradionecrosis.

13. Renal failure.

14. Organ transplant recipients.

15. HIV positive.

16. Malignant diseases.

17. Diseases that compromise the immune system.

18. Unbalanced diabetes mellitus. (HbA1c above 6.5)

19. Psychotic diseases.

20. Hypersensitivity to one of the components of the implant in general and titanium in particular.

21. Women who are pregnant or lactating.

22. Lack of patient cooperation.

23. Uncontrolled endocrine diseases.

24. Any systemic condition that is unbalanced and therefore precludes surgical procedures.

25. Parafunctional habits.- e.g Bruxism.

26. Temporomandibular joint disease.

27. Various pathologies of the oral mucosa for example: Benign mucous pemphigoid, desquamative ginigivitis, erosive lichen planus ,malignancy of oral cavity, bolus erosive diseases of the oral mucosa.

28. Flapless procedures.

Related Conditions & MeSH terms

• Dental Implant Bone Loss
• Implant Clinical Survival

Intervention

Device:
• SPI implant
SPI implant - the original spiral implant

Locations

Country	Name	City	State
China	West China Hospital of Stomatology	Chengdu	Sichuan
China	West China Hospital of Stomatology	Jinan
China	The Affiliated Stomatology Hospital of Tongji University	Shanghai
China	Stomatology Hospital of Shandong University	Yantai

Sponsors (1)

Lead Sponsor	Collaborator
Alpha - Bio Tec Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative Survival Rate		24 months

External Links

•   Sponsor's site